Literature DB >> 17094871

Melatonin premedication and the induction dose of propofol.

A Turkistani1, K M Abdullah, A A Al-Shaer, K F Mazen, K Alkatheri.   

Abstract

BACKGROUND AND OBJECTIVES: Melatonin (N-acetyl-5-methoxytryptamine) is the main indolamine secreted by the pineal gland. Many studies showed that premedication with melatonin is associated with preoperative anxiolysis and sedation without impairment of cognitive and psychomotor skills and without prolonging recovery. We hypothesized that melatonin decreases the amount of propofol required to produce an adequate depth of hypnosis at induction time.
METHODS: After approval from the research committee of the anaesthesia department, informed written consent was taken from 45 adult patients undergoing different surgical procedures. They were allocated randomly into three groups according to the premedication. At 100 min preoperatively, premedication was given in the form of oral melatonin 3 mg (M3 group), oral melatonin 5 mg (M5 group) or no premedication (P group). After preoxygenation an anaesthesiologist who was blinded to the premedication injected propofol 10 mg over 5 s every 15 s until the bispectral index (BIS) score fell to 45. The total dose of propofol required to achieve a BIS score of 45 was recorded. Response to verbal commands and eyelash reflex was evaluated and correlated to the BIS score and propofol dosage. When a BIS score of 45 was reached, tracheal intubation was accomplished after administration of a narcotic and muscle relaxant.
RESULTS: The mean (standard devitation (SD)) induction dose of propofol producing a BIS score of 45 was 134 (25) mg in the placebo group vs. 115 (19.5) and 114 (20.9) mg in the M3 and M5 groups, respectively (P < 0.05). The propofol dose required to achieve loss of eyelash reflex and loss of response to verbal commands was more in the placebo group. Anxiety score as assessed by visual analogue scale (VAS) scored more in the placebo group than both melatonin groups. Time spent in the recovery room did not differ between the three groups.
CONCLUSION: Melatonin premedication, in an oral dose of either 3 or 5 mg, reduced the required dose of propofol to achieve a BIS score of 45, reflecting a sufficient level of hypnosis for tracheal intubation without prolongation of postoperative recovery room stay.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17094871     DOI: 10.1017/S0265021506001505

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  7 in total

Review 1.  Melatonin for pre- and postoperative anxiety in adults.

Authors:  Melissa V Hansen; Natalie L Halladin; Jacob Rosenberg; Ismail Gögenur; Ann Merete Møller
Journal:  Cochrane Database Syst Rev       Date:  2015-04-09

2.  Safety and Efficacy of Oral Melatonin When Combined with Thoracic Epidural Analgesia in Patients with Bilateral Multiple Fracture Ribs.

Authors:  Ahmed M Fetouh Abdelrahman; Amany Faheem Abdel Salam Omara; Alaa Ali M Elzohry
Journal:  Local Reg Anesth       Date:  2020-04-14

3.  The role of melatonin in anaesthesia and critical care.

Authors:  Madhuri S Kurdi; Tushar Patel
Journal:  Indian J Anaesth       Date:  2013-03

4.  Melatonin for preoperative and postoperative anxiety in adults.

Authors:  Bennedikte K Madsen; Dennis Zetner; Ann Merete Møller; Jacob Rosenberg
Journal:  Cochrane Database Syst Rev       Date:  2020-12-08

5.  Melatonin - marvel in the making?

Authors:  Goneppanavar Umesh
Journal:  Indian J Anaesth       Date:  2016-10

6.  Premedication effect of melatonin on propofol induction dose for anesthesia, anxiety, orientation and sedation after abdominal surgery: a double-blinded randomized trial.

Authors:  Afsaneh Norouzi; Shahin Fateh; Hesameddin Modir; Alireza Kamali; Leila Akrami
Journal:  Med Gas Res       Date:  2019 Apr-Jun

7.  Use of melatonin in oral health and as dental premedication.

Authors:  Mercedes Perez-Heredia; Javier Clavero-González; Leticia Marchena-Rodríguez
Journal:  J Biol Res (Thessalon)       Date:  2015-11-19       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.